Islamabad, September 22
Pakistan on Tuesday introduced the launch of the phase-III scientific trials for a possible COVID-19 vaccine being developed by a Chinese firm.
Minister of Planning Asad Umar, who additionally heads the National Command and Operation Centre (NCOC)—a centralised physique set as much as coordinate the nationwide COVID-19 response, mentioned about 8,000 to 10,000 Pakistanis will take part within the trials.
The vaccine is being developed by China’s CanSino Biologics and Pakistan is among the many seven international locations which is able to perform the phase-III trials.
“Just launched the phase 3 trials for a COVID-19 vaccine in Pakistan. Vaccine has been developed by a Chinese company. A total of 40,000 people will participate in this trial in 7 countries, of which 8 to 10, 000 will be Pakistani,” Umar tweeted.
Initial outcomes are anticipated in 4 to 6 months, he added.
The NCOC in a press release mentioned that Pakistan’s National Institute of Health (NIH) had partnered with CanSino to hold out the phase-III trials on people.
Trials for section 1 and a couple of have been held in China, it mentioned.
The NIH Executive Director Maj Gen Aamer Ikram termed it an necessary step for Pakistan to change into part of the trial. PTI